Objective: The purpose of this study was to investigate medication adherence to oral chemotherapy medications and determinants of medication non-adherence to them among gastroenterological cancer patients. Methods: A cross-sectional study was conducted on 117 consecutive, consenting, eligible patients visiting an outpatient clinic of university hospital in Japan. Good medication adherence was defined as taking 100% of the prescribed dose. Medication adherence was measured via self-report. We hypothesized that there was a significant relationship between medication non-adherence and the five factors defined by the World Health Organization: patient-related, socioeconomic-related, condition-related, treatment-related, and healthcare-system/provider-related factors. Multiple logistic regression models were used to identify factors associated with oral chemotherapy medication nonadherence. Results: The proportion of patients showing good medication adherence was 56.4%. The multiple logistic regression analysis revealed that the determinants of medication non-adherence to oral chemotherapy medications included having a history of patient-caused treatment interruptions due to worsening of symptoms (adjusted odds ratio [AOR] = 9.59, 95% confidence interval [CI] = 1.38-66.47), having diarrhea (AOR = 3.25, 95% CI = 1.13-9.34), experiencing pain (AOR = 0.17, 95% CI = 0.05-0.55), taking oral chemotherapy medication every 8 h (AOR = 5.52, 95% CI = 1.71-17.81), and diminished sense of priority for medication (AOR = 1.40, 95% CI = 1.21-1.63). Conclusions: This study suggests that many patients with gastroenterological cancer were nonadherent to oral chemotherapy medications. It might be necessary to conduct periodic screening and connect patients at a high risk of medication non-adherence to appropriate support.
Introduction
Gastroenterological cancer is the most common fatal malignant tumor (1) . Furthermore, the number of gastroenterological cancer patients is increasing, and along with it, the number of relapsed and inoperable patients (1) . Chemotherapy is often the first-choice treatment for such patients, and the number of patients taking oral chemotherapy medications is increasing. Oral chemotherapy has been demonstrated to be effective in suppressing symptoms and prolonging survival (2, 3) . Moreover, oral chemotherapy is often preferred by patients over intravenous chemotherapy, as it decreases the interference of the treatment with their work and social activities, and eliminates the need to travel to the clinic (4, 5) .
To enhance the therapeutic effects of oral chemotherapy medications, it is essential that patients adhere to a prescribed regimen. Medication adherence is defined as 'the extent to which a patient acts in accordance with the prescribed interval and dose of a dosing regimen' (6) . Given that the location where chemotherapy is given is transitioning from inpatient wards to outpatient clinics, it is becoming increasingly necessary for patients and their families to play an active role in ensuring good medication adherence (5) . Furthermore, healthcare providers must play a key role in assessing, educating, and supporting patients in order to improve their adherence to oral chemotherapy medications (5) .
However, previous studies have reported that the rate of oral chemotherapy adherence is generally low among cancer patients (7) (8) (9) . This might be true among gastroenterological cancer patients as well, because some already have digestive symptoms caused by the cancer before beginning chemotherapy. Additionally, patients receiving chemotherapy frequently experience side effects such as nausea, vomiting, diarrhea and fatigue, which can have a significant adverse effect on their quality of life (QOL), especially when combined with the cancer symptoms. Thus, taking oral chemotherapy medication can be a burden to these patients, making medication non-adherence an issue that warrants consideration.
Although scholarly interest in adherence to oral chemotherapy medication among cancer patients has increased in recent decades, there are still rather few studies that have investigated medication adherence among gastroenterological cancer patients (7) (8) (9) . As such, little is known about current medication adherence rates and related factors of non-adherence. This situation makes it difficult to provide effective education and support for patients at risk of medication non-adherence.
The World Health Organization (WHO) proposes five types of factors that might impede medication adherence to therapies: patient-related, socioeconomic-related, condition-related, treatmentrelated, and healthcare-system-and provider-related factors (6) . In cancer patients specifically, various factors have been identified, such as age, gender, cancer stage, duration of chemotherapy, number of medications taken, timing of treatment doses in relation to food intake, burden of taking medication and side effects (7) (8) (9) . It is possible that these and other factors are related to medication nonadherence in gastroenterological cancer patients, in addition to the symptoms and side effects of gastroenterological cancer.
The purpose of this study was to investigate adherence to oral chemotherapy medications and the determinants of medication nonadherence in patients with gastroenterological cancer.
Methods

Study population and data collection
We conducted a cross-sectional study. Patients with gastroenterological cancer were selected from those who consecutively visited the gastroenterology outpatient clinic of The University of Tokyo Hospital. Eligibility criteria were as follows: (i) over 20 years of age, (ii) judged as able to participate in the study by their attending physicians and (iii) were taking oral chemotherapy medications.
Data were collected after patients' medical appointments from August to November 2015 by one of the investigators. Patients completed the questionnaires by themselves. Afterward, the investigator checked for missing responses and, where possible, asked patients to respond to the missing items. Medical data were collected from patients' medical records.
Ethical considerations
The ethics committee of the University of Tokyo approved this study, and all participants provided their written informed consent.
Measurements
The conceptual framework of this study ( Fig. 1) was based on the WHO conceptual model of factors related to medication nonadherence.
Adherence to oral chemotherapy medications Medication adherence was measured in the period between the day on which oral chemotherapy medications were prescribed at the patient's last visit to the hospital to the day of the latest visit (mean ± standard deviation, 28.9 ± 17.4 days) (10, 11) . Medication adherence was defined in terms of the percentage of oral chemotherapy medications taken during this period. During the survey period, we did not exclude those who stopped taking medication without contacting the hospital. An investigator also assessed the prescribed doses of oral chemotherapy medications from patients' medical records. We checked the accuracy of the reported and recorded levels to examine if the prescribed doses of oral chemotherapy medications reported by patients differed from those recorded in their medical records. The rate of adherence to oral chemotherapy medications was calculated using the following formula (12) :
where D pres is the prescribed number of doses of oral chemotherapy medications according to medical records, D miss is the (D miss-pt + D pres-diff ), D miss-pt is the doses of oral chemotherapy medications that patients had missed (based on the questionnaire), and D press-diff is the D pres minus the prescribed number of doses according to patients (based on the questionnaire). Good medication adherence was defined as taking 100% of prescribed doses and medication non-adherence as consumption other than 100% (13) (14) (15) (16) (17) (18) . To avoid social desirability bias, the investigator assured participants that their attending physicians would not be informed of their responses.
Patient-related factors
The following sociodemographic information was collected via the self-administered questionnaire: marital status, cohabitation status and difficulties with oral chemotherapy medications. Age, gender and Eastern Cooperative Oncology Group (ECOG) performance status were collected from patients' medical records.
Difficulties in taking oral chemotherapy medications were measured by adapting a tool used to assess the difficulties in taking medications for ulcerative colitis (19) . The content validity of this tool for the present study was confirmed by two doctors, a certified nurse specialist in cancer nursing, and researchers with experience in chemotherapy administration for gastroenterological cancer. This tool comprises 12 items in three domains, and each item is rated on a 5-point Likert scale from 1 (not at all) to 5 (very much). The item responses are then linearly transformed to a score ranging from 1 to 5 and summed within each domain. Higher scores indicate greater difficulties in taking oral chemotherapy medications. The Cronbach's α coefficients in this study for all domains were over 0.7.
ECOG performance status was measured by the attending physicians using a standardized scoring system. This system yields an objective index of a patient's physical functioning that ranges from 0 (no symptoms) to 4 (bedridden) (20) .
Socioeconomic-related factors
The socioeconomic-related factors assessed using the questionnaire, included employment status, educational status and financial leeway. Financial leeway was rated using a 5-point Likert scale ranging from 1 (not at all) to 5 (very much). Scores of 1-3 were classified as having no financial leeway, while scores of 4 and 5 were classified as having financial leeway.
Condition-related factors
Condition-related factors were obtained from both medical records and the questionnaire: time since diagnosis (months), type of cancer, presence or absence of distant metastasis, subjective symptoms, and anxiety and depression symptoms.
The following cancer-related symptoms or adverse effects were assessed using a dichotomous (yes/no) rating system: fatigue, vomiting, pain, dyspnea, insomnia, appetite loss, constipation and diarrhea.
Anxiety and depression were measured using the Japanese version of the Hospital Anxiety and Depression Scale (HADS). The HADS comprises two domains-anxiety and depression-each containing seven items. These items were rated using a 4-point Likert scale, and the item scores are then summed to create a domain score (21) . Following previous studies, a score of 8 or more in either domain indicates probable anxiety or depression. The validity and reliability of the Japanese version of the HADS have been confirmed (22) .
Treatment-related factors
Treatment-related factors were obtained from the medical records or questionnaire. They included the type of oral chemotherapy medication, history of patient-caused treatment interruptions due to worsening of symptoms, treatment goal (i.e. total body chemotherapy, postoperative adjuvant chemotherapy or preoperative chemotherapy), the duration of taking oral chemotherapy medications (days), the number of times oral chemotherapy medications are taken per day, the timing of taking oral chemotherapy medications (e.g., after a meal, every 8 h), the number of oral chemotherapy medications taken per day, and whether concurrent drip infusion of chemotherapy medication was used. The history of patient-caused treatment interruptions due to worsening of symptoms was assessed via a dichotomous (yes/no) answer to the following question: 'I have stopped taking oral chemotherapy medications without the doctor's instruction because I felt my side effects had worsened when taking them.'
Healthcare-system/provider-related factors The following healthcare-system/provider-related factors were assessed: place of initial treatment (outpatient or inpatient unit), which was collected from medical records, and the level of trust in doctors, which was measured using Anderson's Trust in Physician Scale (23) . This scale comprises nine items rated on a 5-point Likert scale ranging from 1 (not at all) to 5 (very much). A higher score indicates greater trust in the physicians. The validity and reliability of the Japanese version have been confirmed (24) .
Statistical analysis
Descriptive statistics were used to determine the sample's overall adherence to oral chemotherapy medications and participants' characteristics. Chi-squared tests, Fisher's exact tests, and Wilcoxon rank-sum tests were used to compare each set of WHO factors between participants in the good medication adherence group (i.e., those who took 100% of prescribed doses) and those in the medication non-adherence group (those who did not take 100% of prescribed doses). Multivariate logistic regression models were used to identify the independent factors associated with medication nonadherence, adjusted for age (10, 25) , gender (10) and time since diagnosis (10) . Variables with a P value of 0.2 or less in the bivariate analyses were included in a multivariate logistic regression model using the backward variable selection method. Odds ratios and 95% confidence intervals (95% CI) were calculated for each variable in the final model. In all statistical tests, P < 0.05 (two-sided) was regarded as statistically significant. All statistical analyses were performed using SAS 9.4 (SAS institute Inc., Cary NC, USA).
Results
Subjects
Of the 118 patients recruited, 117 agreed to participate in this study. All participants completed the questionnaire (response rate: 99.2%).
Participants' characteristics
Participants' characteristics are shown in Table 1 . The mean participant age was 64.5 years old, 62.4% were men, and the mean time since diagnosis was 26.5 months. The most common type of cancer was colorectal cancer (59.0% 
Adherence to oral chemotherapy medications
The distribution of the medication adherence rate is shown in Table 2 . A total of 56.4% of patients was classified as having good medication adherence. 
Factors related to non-adherence to oral chemotherapy medications
The results of the bivariate analysis of the factors related to medication non-adherence are shown in Table 1 . For patient-related factors, having an ECOG performance status of 0 (P = 0.02) and a diminished sense of priority for medication (P < 0.01) were significantly related to medication non-adherence. Being employed (P = 0.01) was the only significant socioeconomic-related factor. The condition-related factors were being painless (P = 0.02) and having diarrhea (P = 0.04). There were numerous significant treatmentrelated factors: having a history of patient-caused treatment interruptions due to worsening of symptoms (P = 0.02), postoperative adjuvant chemotherapy (P = 0.03), taking oral chemotherapy medications three times a day (P < 0.01), taking oral chemotherapy medications every 8 h (P < 0.01), taking a small number of chemotherapy medications (P = 0.04), and not receiving concurrent drip infusion of chemotherapy medication (P = 0.04). Finally, having received the initial treatment at an outpatient clinic (P < 0.01) was the only significant healthcare-system/provider-related factor.
The results of the multivariate logistic regression analysis are shown in Table 4 . The factors that had a statistically significant association with medication non-adherence, after adjusted for age, gender and time since diagnosis, included having a history of patient-caused treatment interruptions due to worsening of symptoms (adjusted odds ratio (AOR) = 9.59, 95% CI = 1.38-66.47), having diarrhea (AOR = 3.25, 95% CI = 1.13-9.34), experiencing pain (AOR = 0.17, 95% CI = 0.05-0.55), taking oral chemotherapy medications every 8 h (AOR = 5.52, 95% CI = 1.71-17.81), and diminished sense of priority for medication (AOR = 1.40, 95% CI = 1.21-1.63).
Discussion
We investigated adherence to oral chemotherapy medications and the determinants of non-adherence among gastroenterological cancer patients. The proportion of patients showing good medication adherence was 56.4%. The factors related to medication non-adherence were having a history of patient-caused treatment interruptions due to worsening of symptoms, having diarrhea, experiencing pain, taking oral chemotherapy medications every 8 h, and diminished sense of priority for medication.
According to previous studies of self-reported adherence to oral chemotherapy medications,~67.0-88.0% of the subjects were classified as having good medication adherence when using the 100% cutoff (13) (14) (15) (16) (17) (18) . While a comparison between our study and these previous ones is not exact-all of these previous studies included patients with non-gastroenterological cancers-the proportion of patients showing good medication adherence in this study was much lower. These results suggest that it would be necessary to improve medication adherence by helping identify gastroenterological cancer patients at high risk of medication non-adherence through periodic screening and then connecting them with the appropriate education and support.
Having a history of patient-caused treatment interruptions due to worsening of symptoms was associated with medication nonadherence. According to a survey of chronic disease patients, 18.3% reported having decided on their own to either reduce the dosage or discontinue use of their medication at some point in the past. The reasons for this were burden of taking prescribed medications and side effects (26) . Similar results were reported in a previous study on cancer patients (27) . In this study, 10.3% of participants had a history of patient-caused treatment interruptions due to concerns over worsening of symptoms. Some cancer patients decide to discontinue treatment as a coping mechanism for the diminished symptoms combined with worsening side effects; as such, some of the patients in the medication non-adherence group might have decided to stop taking their medications to cope with side effects, as in the past.
In this study, having diarrhea was associated with medication non-adherence. Diarrhea is a symptom accompanying progression of gastroenterological cancer, and it is also a frequent side effect of oral chemotherapy medications. Diarrhea caused by chemotherapy medications is usually severe for gastroenterological cancer patients (28) and can lead to a deterioration in nutritional status, dehydration, and physical weakness if it continues. Numerous previous studies have reported that the side effects of oral chemotherapy medications can influence medication non-adherence (9), and diarrhea might be a particularly noteworthy side effect that contributes to non-adherence among gastroenterological cancer patients. Fortunately, severe diarrhea can be avoided by taking anti-diarrhea Subjective symptoms are a major side effect of oral chemotherapy. However, it can be difficult for both medical staff to grasp the severity of symptoms such as fatigue or skin conditions through objective assessment; accordingly, there is a gap between how medical staff and patients evaluate side effects (29, 30) . All patients must know how to monitor the appearance of expected side effects in the early stages and how to ask for healthcare support, especially considering that symptoms can quickly escalate in the home setting. Similarly, healthcare providers should be engaged in in-depth communication with patients to understand patients' concerns regarding side effects or the worsening of their condition as a result of taking oral chemotherapy medications. Individualized coaching provided by nurses could help with side effect management and might provide strategies that can aid patients in remembering to take their medications as prescribed. On the other hand, patients in this study might have been told by their physicians to stop taking oral chemotherapy medication when symptoms worsen. Because these patients would have chosen to not ingest the oral chemotherapy medications as part of their self-management, they could not be considered to be non-adherent in the strictest sense. However, there is no prior research indicating the extent of this practice, so further study would be needed. Experiencing pain was associated with lower medication nonadherence. Pain, such as abdominal pain, typically appears in patients with gastroenterological cancer progression and metastasis. As such, patients with pain might have adhered to their medications to maximize its potential therapeutic effect, whereas patients without pain might have believed that their cancer was in decline (15, 18) . To improve medication adherence among patients who do not experience pain, it might be important to provide them with sufficient knowledge of their disease and the therapeutic effects of the medications.
Taking oral chemotherapy medications every 8 h was associated with medication non-adherence. In this study, over 60% of participants using UFT ® , which is recommended to be taken every 8 h, were medication non-adherent; this percentage was the highest among the medications included in this study. Because no significant difference in background factors between UFT ® and other medications was found, this low adherence rate might be associated with the timing that the medications are taken. If the medication schedule does not fit well into the lifestyle routine of each individual patient, he/she might forget to take the medications (31) . This would be related to differences between mealtimes and timing of medications (32) . However, most patients might find it difficult to change habits. Healthcare providers should attempt to understand individual patients' characteristics and lifestyles and develop plans alongside patients for incorporating medicationtaking behavior into daily practice. If possible, it could be useful to investigate whether medication administration can be changed to shorter intervals. It also might be helpful to educate patients on how to write a medication record, which could help them form a habit of medication-taking behaviors. Diminished sense of priority for medication was associated with medication non-adherence. This has been mentioned before in patients with other types of cancer or chronic diseases (7, 33) . To improve patients' prioritization of taking medication, it might be effective to suggest feasible, concrete methods for use in daily life, such as putting medications prominently in view, using a pill case, or asking family members to remind patients to take their medications at the appropriate time. Moreover, prioritization might be enhanced if medical staff explain that continuing oral chemotherapy medications contributes to improved QOL and prolongs survival. Education based on health behavior models such as the Health Belief Model, which has been used for patients with other chronic diseases, could be effective when providing these explanations (34) .
Limitation
This study has several limitations. The first concerns the generalizability of the results. This study was conducted at a single university hospital in Tokyo. Additionally, of the oral chemotherapy medications clinically introduced to participants during the study period, a portion (e.g., Stivarga ® ) were not included in this study. Furthermore, because there were few patients taking each type of medication, we could not analyze differences in adherence between the specific reagents. These points should be noted when attempting to generalize the results of this study. In future studies, it would therefore be necessary recruit more subjects taking each type of medication, and include other variables (e.g., dose reduction), with the goal of investigating the factors related to adherence to each medication in detail. Future studies should also include multiple facilities.
The second limitation concerns the precision of our measurement of medication adherence. Since there is no gold standard method for measuring medication adherence, it is often recommended to use multiple measures and evaluate the level of agreement between these measures (8, 9) . This study used a self-report method, which has the advantage of being easily applied in clinical settings and placing minimal burden on patients. However, the risk of recall bias and social desirability are disadvantages of this method, and might have led to overestimations of medication adherence. In future studies, researchers should employ more accurate measures of medication adherence, such as those relying on urine or blood samples.
The third limitation concerns the different medication adherence evaluation periods for each participant. Individuals with longer measurement periods naturally took larger doses of the oral chemotherapy medication compared to those with shorter measurement periods. This might lead to underestimation of medication adherence. For future studies, we will conduct this type of assessment using consistent measurement periods across all regimens and medication types. The final limitation concerns the lack of our ability to infer causal relationships due to the cross-sectional nature of our study. In the future, longitudinal studies would be necessary to determine the related factors that cause medication non-adherence.
Conclusions
This study examined adherence to oral chemotherapy medications and the determinants of medication non-adherence among patients with gastroenterological cancer. The proportion of patients showing good medication adherence was 56.4%, which suggests that many patients with gastroenterological cancer were non-adherent to oral chemotherapy medications. The determinants of medication nonadherence included having a history of patient-caused treatment interruptions due to worsening of symptoms, having diarrhea, being painless, taking oral chemotherapy medications every 8 h, and diminished sense of priority for medication. Healthcare providers should attempt to understand individual patients' characteristics and lifestyles and develop plans alongside patients for incorporating medication-taking behavior into daily practice. Additionally, healthcare providers might be needed to offer specific ways of coping with side effects of oral chemotherapy medications. 
